A new study suggests that people with Alzheimer’s on the drug risperidone, an antipsychotic drug often prescribed as the brand name Risperdal, may be better off continuing to take the drug if they have not experienced negative side effects.
Because of the potential side effects, risperidone is only recommended to be prescribed for three to six months. After that point, a written explanation is required to continue the drug. A study, published in the New England Journal of Medicine and funded by the National Institutes of Health, investigated the effects of discontinuing the medication among individuals who had seen improvements as a result of the drug. Researchers prescribed risperidone to individuals with Alzheimer’s disease who showed signs of agitation and aggression. After 16 weeks, researchers put half of the individuals who did well on the drug on a placebo. The other half continued the treatment. The study found that those on the placebo were twice as likely to have their symptoms return. The rate of side effects and death were equal among the two groups.
Researchers warned that antipsychotics can carry the risk of serious side effects and should not be used on all individuals with Alzheimer’s disease, but discontinuing medication that has achieved benefits is not always the right choice. "One must be cautious about discontinuing the medication,” said study author Dr. D.P. Devanand, director of the division of geriatric psychiatry at Columbia Psychiatry and the New York State Psychiatric Institute in New York City. “If a person does well on it and there are not too many side effects, maybe they should stay on it for a while and be monitored closely."
For more information, read the article: Some With Alzheimer's Better Off Staying on Antipsychotics: Study Or, read the full study: Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease.
End of Life, Engage, Managed Risk, Membership, Memory Care Best Practices and Research, Memory Care Education
The Alzheimer’s Foundation of America has announced that National Memory Screening Week will take place the first week of November and participating s...
Facts and Figures, Memory Care Best Practices and Research, Memory Care Education, Reports
There are currently about 46.8 million people around the globe living with dementia with those figures expected to nearly double every 20 years, find...
Facts and Figures, Medication Management, Reports
More than 70 percent of Americans feel that drug costs are unreasonable and that drug companies are more concerned with profits than people, according...
ALFA Events, Business Planning, CEO, cheatsheet, Clinical Quality and Quality Care Delivery, Engage, Human Resources and Organizational Development, Membership, Professional Development, Senior Living Leadership Forum
Join fellow members of ALFA’s Executive Roundtables and President’s Council at the annual Senior Living Executive Forum, Oct. 21-22 at the Omni Rancho...
The Consumer Financial Protection Bureau continues to roll out resources to help families and caregivers manage finances of older adults with a new su...
The Dementia Action Alliance has a released a new report outlining language use related to dementia, noting that these words currently used to describ...
Business Planning, cheatsheet, Disabilities, Memory Care Best Practices and Research, Senior Living Options, Value-Added Amenities and Services
Senior living providers are discovering that when it comes to serving residents with cognitive impairments, senior housing needs to do the things it a...
Disabilities, Falls Prevention, Health and Wellness, Managed Risk
The National Council on Aging is offering a webinar Aug. 13 on new resources and tools to use in falls prevention efforts and for Falls Prevention Awa...
End of Life, Engage, Health and Wellness, Memory Care Best Practices and Research, Memory Care Education
Volunteers are needed for clinical trials focusing on Alzheimer’s and related research. To find out more, click on a trial name below and contact the ...
End of Life, Health and Wellness, Managed Risk, Memory Care Best Practices and Research, Memory Care Education
US Against Alzheimer’s, the Mayo Clinic and two universities have been approved for a three-year contract of up to $1.56 million by the Patient-Center...